default author photo

Charles Landen

University of Alabama at Birmingham

Birmingham, AL 35294-4460

United States

  • University of Alabama at Birmingham

SCHOLARLY PAPERS

1

DOWNLOADS

66

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Benefit from the Immune Checkpoint Inhibitor Atezolizumab Addition in Poor Prognostic Ovarian Cancer Patients : Imagyn050 Trial

Number of pages: 20 Posted: 11 Feb 2025
Benoit You, Charles Anderson, Sabrina Chiara Cecere, Aurore Carrot, Tashanna Myers, Florian Heitz, Sudarshan Sharma, Fatih Selcukbiricik, Carol Aghajanian, Josefin Fernebro, Stephanie V. Blank, Maria Elena Laudani, Premal Thaker, Mayu Yunokama, Lyndsay Wilmott, Alla Lisyanskaya, Roberto Hegg, Yvette He, Charles Landen, Yvonne G. Lin, Jesus Alarcon and Kathleen N. Moore
Université Lyon 1 - Faculty of Medicine Lyon-Sud, affiliation not provided to SSRN, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Université de Lyon - Université Claude Bernard Lyon 1, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Koc University - School of Medicine, Memorial Sloan Kettering Cancer Center, affiliation not provided to SSRN, Mount Sinai Health System - Icahn School of Medicine, University of Turin, Siteman Cancer Center, Japanese Foundation for Cancer Research, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Alabama at Birmingham, affiliation not provided to SSRN, Hospital Universitari Son Espases and University of Oklahoma - Stephenson Cancer Center
Downloads 66 (916,100)

Abstract:

Loading...

Ovarian Neoplasms, Immune checkpoint inhibitors, atezolizumab [Supplementary Concept], CA-125 antigen, Prognosis